Mikhail Kulak, PhD
Founder · CSO
Scientist-founder with 20+ years in molecular biology. Former Assistant Professor at the University of Iowa. 87 publications and an h-index of 20.
The bottleneck is discovery.
The world fishes one known target at a time.
We map the entire ocean.
The bottleneck is discovery.
The world fishes one known target at a time.
We map the entire ocean.
Comparison
Conventional Discovery
Bet everything on one target before you know it works.
- Need a known target to start
- Hit identification outside living biology — requires cell-based assay development
- One target, one shot — most never pan out. Risk of wasted years of research
- Expensive libraries ($12–$120 per peptide)
- Limited to 7–15 aa
1drug candidate3–5 years
SageneX Discovery
Find the expected therapeutic outcome, then reverse-engineer the mechanism of action.
- Target-agnostic
- On-cell HIT discovery — drastically reduced hit-to-lead optimization
- Multiple pairs of actionable targets and hits identified
- Up to 1,000× lower library cost ($0.12 per peptide)
- Covers 7–50 aa space
100–200drug candidates6–12 months
